Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01225887 · ClinicalTrials.gov registry record · Phase 2
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase 2 study of Endometrial Adenocarcinoma and Endometrial Serous Adenocarcinoma, sponsored by Gynecologic Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 37
- Enrollment target
- 20
- Study locations
NCT01225887: Completed Phase 2 study of Endometrial Adenocarcinoma and Endometrial Serous Adenocarcinoma, sponsored by Gynecologic Oncology Group.
NCT01225887 is a Phase 2 study of Endometrial Adenocarcinoma and Endometrial Serous Adenocarcinoma that has completed, run by Gynecologic Oncology Group. The registered enrollment target is 37 participants, below the 337-participant average among 13 other Endometrial Adenocarcinoma trials with a reported enrollment target (89% lower). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01225887, a Phase 2 study of Endometrial Adenocarcinoma and Endometrial Serous Adenocarcinoma, has completed, sponsored by Gynecologic Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 37 participants
- Enrollment target
- 20
- Study locations
Study Summary
This phase II trial studies the side effects and how well nintedanib works in treating patients with endometrial cancer that has come back. Nintedanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the tumor.
Primary Outcome
The incidence of adverse events (grade 3 or higher) as assessed by the National Cancer Institute CTCAE version 4.0
Conditions Studied
Interventions
- DRUG Nintedanib
Study Locations (20)
Michigan
- Saint Joseph Mercy Hospital - Ann Arbor
- Michigan Cancer Research Consortium NCORP - Ann Arbor
- Hurley Medical Center - Flint
- Genesys Regional Medical Center - Grand Blanc
- Allegiance Health - Jackson
- Borgess Medical Center - Kalamazoo
- Bronson Methodist Hospital - Kalamazoo
Illinois
- Northwestern University - Chicago
- NorthShore University HealthSystem-Evanston Hospital - Evanston
- Sudarshan K Sharma MD Limted-Gynecologic Oncology - Hinsdale
Indiana
- Indiana University/Melvin and Bren Simon Cancer Center - Indianapolis
- Saint Vincent Oncology Center - Indianapolis
Maryland
- Greater Baltimore Medical Center - Baltimore
- MedStar Franklin Square Medical Center/Weinberg Cancer Institute - Baltimore
California
- Providence Saint Joseph Medical Center/Disney Family Cancer Center - Burbank
Colorado
- University of Colorado Cancer Center - Anschutz Cancer Pavilion - Aurora
Connecticut
- Smilow Cancer Hospital Care Center at Saint Francis - Hartford
Georgia
- Memorial University Medical Center - Savannah
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2011-10 |
| Est. Completion | 2016-01 |
| Phase | Phase 2 |
What the finished NCT01225887 record still lists
NCT01225887 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 37 participants, a relatively small participant target, below the 337-participant average among 13 other Endometrial Adenocarcinoma trials with a reported enrollment target (89% lower).
The record links to 9 conditions, with Endometrial Adenocarcinoma appearing as the primary indexed condition, and to 1 intervention - of which Nintedanib is the first listed.
NCT01225887 names 20 study sites across 10 states, led by Michigan, Illinois, Indiana.
Frequently Asked Questions
What is clinical trial NCT01225887 about?
NCT01225887 is a clinical study titled "Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer". This phase II trial studies the side effects and how well nintedanib works in treating patients with endometrial cancer that has come back. Nintedanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the tumor.
What is the current status of trial NCT01225887?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 37 participants. The study started on 2011-10. Estimated completion is 2016-01.
What conditions does trial NCT01225887 study?
This clinical trial studies the following conditions: Endometrial Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Recurrent Uterine Corpus Carcinoma, Endometrial Undifferentiated Carcinoma.
What interventions are being tested in trial NCT01225887?
The interventions under investigation include: Nintedanib (DRUG).
Who is sponsoring clinical trial NCT01225887?
This trial is sponsored by Gynecologic Oncology Group, which has 154 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01225887 being conducted?
This trial has 20 study locations across California, Colorado, Connecticut, Georgia, Idaho. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Endometrial Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01225887's enrollment target sits among peer trials
37 9th of 13 higher than 4 of 13 other Endometrial Adenocarcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Endometrial Adenocarcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
RECRUITING · Phase 2
-
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
RECRUITING · Phase 2
-
Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone
ACTIVE NOT RECRUITING · Phase 2
-
Study of BMS-986205 and Nivolumab in Endometrial Cancer or Endometrial Carcinosarcoma That Has Not Responded to Treatment
ACTIVE NOT RECRUITING · Phase 2
-
Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Trastuzumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02800486 · 37 participants · Phase 2
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
- NCT03173937 · 37 participants · Phase 1
Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome
- NCT03295227 · 37 participants · Phase 1
Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer
- NCT03401047 · 37 participants · Early Phase 1
Study to Assess Potential Impairments in Estradiol Augmentation of Gonadotropin Secretion in Polycystic Ovary Syndrome
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia